Hepatitis B virus reactivation in cancer patients receiving direct‐acting antivirals for hepatitis C virus infection

2021 ◽  
Vol 28 (5) ◽  
pp. 844-848
Author(s):  
Haley Pritchard ◽  
Jessica P. Hwang ◽  
Georgios Angelidakis ◽  
Marcel Yibirin ◽  
Lan Wang ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Virus Reactivation ◽  
Hepatitis C Virus Infection ◽  
Direct Acting Antivirals ◽  
Hepatitis B Virus Reactivation ◽  
B Virus ◽  
Direct Acting

Risk of hepatitis B virus reactivation with direct-acting antivirals against hepatitis C virus: A cohort study from Egypt and meta-analysis of published data

2018 ◽  
Vol 38 (12) ◽  
pp. 2159-2169 ◽  
Author(s):  
Mohamed El Kassas ◽  
Yusuke Shimakawa ◽  
Zainab Ali-Eldin ◽  
Anna-Louise Funk ◽  
Mohamed Naguib Wifi ◽  
...  
Keyword(s):  
Cohort Study ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Meta Analysis ◽  
Published Data ◽  
Virus Reactivation ◽  
Direct Acting Antivirals ◽  
Hepatitis B Virus Reactivation ◽  
B Virus ◽  
Direct Acting

scholarly journals Hepatitis B virus reactivation sustained by a hepatitis B virus surface antigen immune-escape mutant isolate in a patient who was hepatitis B core antibody positive during treatment with sofosbuvir and velpatasvir for hepatitis C virus infection: a case report

2019 ◽  
Vol 13 (1) ◽  
Author(s):  
Luca Foroghi Biland ◽  
Ludovica Ferrari ◽  
Vincenzo Malagnino ◽  
Elisabetta Teti ◽  
Carlotta Cerva ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Virus Reactivation ◽  
Virus Surface ◽  
Hepatitis B Virus Reactivation ◽  
B Virus

Abstract Background Although several cases of hepatitis B virus reactivation have been described in patients with a history of hepatitis B virus infection while undergoing treatment for hepatitis C virus infection with direct acting antivirals, the question of whether hepatitis B virus surface antigen immune-escape mutations might play a role has not been addressed so far. Case presentation We report a case of hepatitis B virus reactivation in a Caucasian patient infected with hepatitis C virus during treatment with sofosbuvir and velpatasvir. A 50-year-old man with a genotype 1a hepatitis C virus infection was considered for therapy. His serological profile was hepatitis B virus surface antigen-negative, hepatitis B virus core antibody-positive, hepatitis B virus surface antibody-negative, and anti-hepatitis D virus-positive. The detection of hepatitis B virus deoxyribonucleic acid (DNA) indicated active viral replication during the direct acting antiviral treatment that spontaneously returned to undetectable levels after treatment completion. Starting from week 12 after the end of treatment, hepatitis B virus surface antibody titers and hepatitis B virus e antibody developed. Sequencing analysis revealed the hepatitis B virus genotype D3 and the presence of two relevant immune-escape mutations (P120S and T126I) in the major hydrophilic region by analyzing the S region. Conclusions We speculate that the presence of the hepatitis B virus surface antigen mutations, endowed with the enhanced capability to elude the immune response, could play a role in hepatitis B virus reactivation. This observation confirms that occult hepatitis B infection should also be carefully monitored, through surveillance of the hepatitis B virus viral load before and during direct acting antiviral treatment of hepatitis C virus.

Sign in / Sign up

Export Citation Format

Share Document